These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
249 related articles for article (PubMed ID: 29248549)
1. A role of SIPL1/SHARPIN in promoting resistance to hormone therapy in breast cancer. Ojo D; Wu Y; Bane A; Tang D Biochim Biophys Acta Mol Basis Dis; 2018 Mar; 1864(3):735-745. PubMed ID: 29248549 [TBL] [Abstract][Full Text] [Related]
2. Polycomb complex protein BMI1 confers resistance to tamoxifen in estrogen receptor positive breast cancer. Ojo D; Lin X; Wu Y; Cockburn J; Bane A; Tang D Cancer Lett; 2018 Jul; 426():4-13. PubMed ID: 29626519 [TBL] [Abstract][Full Text] [Related]
3. Tumor-associated macrophages secrete CC-chemokine ligand 2 and induce tamoxifen resistance by activating PI3K/Akt/mTOR in breast cancer. Li D; Ji H; Niu X; Yin L; Wang Y; Gu Y; Wang J; Zhou X; Zhang H; Zhang Q Cancer Sci; 2020 Jan; 111(1):47-58. PubMed ID: 31710162 [TBL] [Abstract][Full Text] [Related]
4. Elevation of SIPL1 (SHARPIN) Increases Breast Cancer Risk. De Melo J; Tang D PLoS One; 2015; 10(5):e0127546. PubMed ID: 25992689 [TBL] [Abstract][Full Text] [Related]
5. A miR-26a/E2F7 feedback loop contributes to tamoxifen resistance in ER-positive breast cancer. Liu J; Li X; Wang M; Xiao G; Yang G; Wang H; Li Y; Sun X; Qin S; Du N; Ren H; Pang Y Int J Oncol; 2018 Oct; 53(4):1601-1612. PubMed ID: 30066905 [TBL] [Abstract][Full Text] [Related]
6. Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and β1-integrin signaling pathway in tumor cells. Yuan J; Liu M; Yang L; Tu G; Zhu Q; Chen M; Cheng H; Luo H; Fu W; Li Z; Yang G Breast Cancer Res; 2015 May; 17(1):69. PubMed ID: 25990368 [TBL] [Abstract][Full Text] [Related]
7. Estrogen receptor-α variant, ER-α36, is involved in tamoxifen resistance and estrogen hypersensitivity. Zhang X; Wang ZY Endocrinology; 2013 Jun; 154(6):1990-8. PubMed ID: 23546601 [TBL] [Abstract][Full Text] [Related]
8. Role of RBP2-Induced ER and IGF1R-ErbB Signaling in Tamoxifen Resistance in Breast Cancer. Choi HJ; Joo HS; Won HY; Min KW; Kim HY; Son T; Oh YH; Lee JY; Kong G J Natl Cancer Inst; 2018 Apr; 110(4):. PubMed ID: 29028222 [TBL] [Abstract][Full Text] [Related]
9. Tamoxifen-resistant breast cancer cells are resistant to DNA-damaging chemotherapy because of upregulated BARD1 and BRCA1. Zhu Y; Liu Y; Zhang C; Chu J; Wu Y; Li Y; Liu J; Li Q; Li S; Shi Q; Jin L; Zhao J; Yin D; Efroni S; Su F; Yao H; Song E; Liu Q Nat Commun; 2018 Apr; 9(1):1595. PubMed ID: 29686231 [TBL] [Abstract][Full Text] [Related]
10. Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression. Raha P; Thomas S; Thurn KT; Park J; Munster PN Breast Cancer Res; 2015 Feb; 17(1):26. PubMed ID: 25848915 [TBL] [Abstract][Full Text] [Related]
11. Down-regulation of Forkhead box protein A1 (FOXA1) leads to cancer stem cell-like properties in tamoxifen-resistant breast cancer cells through induction of interleukin-6. Yamaguchi N; Nakayama Y; Yamaguchi N J Biol Chem; 2017 May; 292(20):8136-8148. PubMed ID: 28270510 [TBL] [Abstract][Full Text] [Related]
12. OCT-4: a novel estrogen receptor-α collaborator that promotes tamoxifen resistance in breast cancer cells. Bhatt S; Stender JD; Joshi S; Wu G; Katzenellenbogen BS Oncogene; 2016 Nov; 35(44):5722-5734. PubMed ID: 27065334 [TBL] [Abstract][Full Text] [Related]
13. KLF4 overcomes tamoxifen resistance by suppressing MAPK signaling pathway and predicts good prognosis in breast cancer. Jia Y; Zhou J; Luo X; Chen M; Chen Y; Wang J; Xiong H; Ying X; Hu W; Zhao W; Deng W; Wang L Cell Signal; 2018 Jan; 42():165-175. PubMed ID: 28988130 [TBL] [Abstract][Full Text] [Related]
14. Low GPR81 in ER Yu J; Du Y; Liu C; Xie Y; Yuan M; Shan M; Li N; Liu C; Wang Y; Qin J Life Sci; 2024 Aug; 350():122763. PubMed ID: 38823505 [TBL] [Abstract][Full Text] [Related]
15. Loss of B-cell translocation gene 2 expression in estrogen receptor-positive breast cancer predicts tamoxifen resistance. Takahashi M; Hayashida T; Okazaki H; Miyao K; Jinno H; Kitagawa Y Cancer Sci; 2014 Jun; 105(6):675-82. PubMed ID: 24698107 [TBL] [Abstract][Full Text] [Related]
16. MCAM/CD146 promotes tamoxifen resistance in breast cancer cells through induction of epithelial-mesenchymal transition, decreased ERα expression and AKT activation. Liang YK; Zeng D; Xiao YS; Wu Y; Ouyang YX; Chen M; Li YC; Lin HY; Wei XL; Zhang YQ; Kruyt FA; Zhang GJ Cancer Lett; 2017 Feb; 386():65-76. PubMed ID: 27838413 [TBL] [Abstract][Full Text] [Related]
17. GPER mediates decreased chemosensitivity via regulation of ABCG2 expression and localization in tamoxifen-resistant breast cancer cells. Yu T; Cheng H; Ding Z; Wang Z; Zhou L; Zhao P; Tan S; Xu X; Huang X; Liu M; Peng M; Qiu YA Mol Cell Endocrinol; 2020 Apr; 506():110762. PubMed ID: 32087276 [TBL] [Abstract][Full Text] [Related]
18. The phenomenon of acquired resistance to metformin in breast cancer cells: The interaction of growth pathways and estrogen receptor signaling. Scherbakov AM; Sorokin DV; Tatarskiy VV; Prokhorov NS; Semina SE; Berstein LM; Krasil'nikov MA IUBMB Life; 2016 Apr; 68(4):281-92. PubMed ID: 26892736 [TBL] [Abstract][Full Text] [Related]
19. Mammalian enabled protein enhances tamoxifen sensitivity of the hormone receptor-positive breast cancer patients by suppressing the AKT signaling pathway. He L; She C; Jiang S; Qi Z; Deng Z; Ji L; Cui Y; Wu J Biol Direct; 2024 Mar; 19(1):21. PubMed ID: 38459605 [TBL] [Abstract][Full Text] [Related]
20. Aromatase and breast cancer. Brodie A; Sabnis G; Jelovac D J Steroid Biochem Mol Biol; 2006 Dec; 102(1-5):97-102. PubMed ID: 17113978 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]